These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17293390)

  • 1. Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.
    Di Palma S; Collins N; Faulkes C; Ping B; Ferns G; Haagsma B; Layer G; Kissin MW; Cook MG
    J Clin Pathol; 2007 Sep; 60(9):1067-8. PubMed ID: 17293390
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
    Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
    Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer.
    Di Palma S; Collins N; Bilous M; Sapino A; Mottolese M; Kapranos N; Schmitt F; Isola J
    J Clin Pathol; 2008 Jun; 61(6):757-60. PubMed ID: 18326010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mRNA in situ hybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish study.
    Bernet L; Martinez Benaclocha M; Castera C; Cano Muñoz R; Sevilla F; Alba J; de Dios Barranco J; Cordoba A; Garcia-Caballero T; Hardisson D; de Francisco Hernandez JM; Lazaro JM; Polo L; Riu F; Rezola R; Rojo F; Ruiz I; Hernándiz A; de la Cámara de Las Heras JM; Coupe VM
    Diagn Mol Pathol; 2012 Jun; 21(2):84-92. PubMed ID: 22555091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [HER2 gene amplification assay: is CISH an alternative to FISH?].
    Denoux Y; Arnould L; Fiche M; Lannes B; Couturier J; Vincent-Salomon A; Penault-Llorca F; Antoine M; Balaton A; Baranzelli MC; Becette V; Bellocq JP; Bibeau F; Ettore F; Fridman V; Gnassia JP; Jacquemier J; MacGrogan G; Mathieu MC; Migeon C; Rigaud C; Roger P; Sigal-Zafrani B; Simony-Lafontaine J; Trassard M; Treilleux I; Verriele V; Voigt JJ;
    Ann Pathol; 2003 Dec; 23(6):617-22. PubMed ID: 15094603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.
    Riethdorf S; Hoegel B; John B; Ott G; Fritz P; Thon S; Loening T; Pantel K
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):261-9. PubMed ID: 20396915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.
    Pedersen M; Rasmussen BB
    Diagn Mol Pathol; 2009 Jun; 18(2):96-102. PubMed ID: 19430295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Assessment of HER2 status in breast cancer].
    Penault-Llorca F; Cayre A
    Bull Cancer; 2004 Dec; 91 Suppl 4():S211-5. PubMed ID: 15899610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A; Bronsard M; Lemieux R; Geha S
    Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
    Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
    Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HER2 CISH pharmDx(™) Kit in the assessment of breast cancer patients for anti-HER2 treatment.
    Foged NT; Brügmann A; Jørgensen JT
    Expert Rev Mol Diagn; 2013 Apr; 13(3):233-42. PubMed ID: 23570400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era.
    Vocaturo A; Novelli F; Benevolo M; Piperno G; Marandino F; Cianciulli AM; Merola R; Donnorso RP; Sperduti I; Buglioni S; Mottolese M
    Oncologist; 2006 Sep; 11(8):878-86. PubMed ID: 16951391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
    Bilous M; Morey A; Armes J; Cummings M; Francis G
    Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.
    Sáez A; Andreu FJ; Seguí MA; Baré ML; Fernández S; Dinarés C; Rey M
    Breast; 2006 Aug; 15(4):519-27. PubMed ID: 16290155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations.
    Gong Y; Sweet W; Duh YJ; Greenfield L; Fang Y; Zhao J; Tarco E; Symmans WF; Isola J; Sneige N
    Am J Clin Pathol; 2009 Apr; 131(4):490-7. PubMed ID: 19289584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis of HER2 gene amplification in breast carcinoma].
    Couturier J; Vincent-Salomon A; Mathieu MC; Valent A; Bernheim A
    Pathol Biol (Paris); 2008 Sep; 56(6):375-9. PubMed ID: 18456424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HER-2 diagnostics].
    Bánkfalvi A
    Magy Onkol; 2002; 46(1):11-5. PubMed ID: 12050677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of dual immunohistochemistry and chromogenic in situ hybridization for HER2 on a single section.
    Reisenbichler ES; Horton D; Rasco M; Andea A; Hameed O
    Am J Clin Pathol; 2012 Jan; 137(1):102-10. PubMed ID: 22180483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of reliability of FISH versus brightfield dual-probe in situ hybridization (BDISH) for frontline assessment of HER2 status in breast cancer samples in a community setting: influence of poor tissue preservation.
    Schiavon BN; Jasani B; de Brot L; Vassallo J; Damascena A; Cirullo-Neto J; Ivanildo Neves J; Augusto Soares F; Gobbi H; Malagoli Rocha R
    Am J Surg Pathol; 2012 Oct; 36(10):1489-96. PubMed ID: 22982892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.